In a wide-ranging interview CEO Bertrand Ducrey introduces Debiopharm’s unique business focus on drug improvement, drug delivery, and drug targeting; recent progress in oncology, including an FDA breakthrough designation and out-licensing deal for its head and neck cancer product; as well as a host of other topics, including the company’s investment fund, AI integration, and antimicrobial resistance (AMR).
It is in our DNA to look for and assess opportunities. We assess around 500 potential product opportunities per year with the aim of in-licensing only one or two
